Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-HTP and Creatine for Antidepressant Augmentation in SSRI/SNRI-resistant MDD
NCT05895747Phase 2Recruiting
- Sponsor
- University of Utah
- Start
- Sep 2023
- Primary completion
- Jul 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 5-hydroxytryptophan, creatine in major depressive disorder (MDD), sponsored by University of Utah. Started Sep 2023; status: recruiting.
02
Drugs
5-hydroxytryptophancreatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05895747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895747.